经导管动脉化疗栓塞联合姜黄素治疗肝癌疗效及预后评估

Efficacy and Prognosis of Transcatheter Arterial Chemoembolization Combined with Curcumin in the Treatment of Liver Cancer

目的探讨经导管动脉化疗栓塞术(TACE)联合姜黄素治疗肝癌的临床疗效及预后。方法选取医院2016年6月至2018年4月收治的原发性肝癌患者80例,随机分为治疗组和对照组,各40例。两组均予以TACE治疗,治疗组加用姜黄素。结果治疗组缓解率为47.50%,控制率为97.50%,均明显高于对照组的25.00%和82.50%(P<0.05);治疗后,两组患者肿瘤大小、血清甲胎蛋白(AFP)、肝功能指标水平均明显低于治疗前,且治疗组改善情况显著优于对照组(P<0.05);治疗后,治疗组患者的卡氏生活质量量表(KPS)评分明显高于对照组(P<0.05);经随访,治疗组术后0.5,1,2年生存率均高于对照组(P<0.05),术后1,2年复发率均低于对照组(P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论TACE联合姜黄素治疗原发性肝癌临床疗效显著,可改善临床症状,延长患者的生存时间,改善生存质量,且安全有效。

Objective To investigate the clinical efficacy and prognosis of transcatheter arterial chemoembolization(TACE)combined with curcumin in the treatment of liver cancer.Methods Totally 80 patients with primary liver cancer admitted to our hospital from June2016 to April 2018 were selected and randomly divided into the treatment group and the control group,40 cases in each group.The patients in the two groups were treated with TACE,on this basis,the patients in the treatment group were treated with curcumin.Results The effective rate and control rate of the treatment group were 47.50%and 97.50%,which were significantly higher than25.00%and 82.50%of the control group(P<0.05).After treatment,the tumor size,serum alpha-fetoprotein(AFP)and indexes of liver function in the two groups were significantly lower than those before treatment,and the improvement of the treatment group was significantly better than that of the control group(P<0.05).After treatment,the KPS score in the treatment group was significantly higher than that in the control group(P<0.05).After follow-up,the survival rates of 0.5,1 and 2 years after operation in the treatment group were higher than those in the control group(P<0.05),and the recurrence rates of 1 and 2 years after operation in the treatment group were lower than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion TACE combined with curcumin in the treatment of primary liver cancer has significant clinical efficacy,it can improve the clinical symptoms,prolong the survival time of patients and improve the quality of life,which is safe and effective.